Compare Lululemon Athletica Inc (LULU) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Lululemon Athletica Inc trades at $93.58 (market cap $10.44B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Lululemon Athletica Inc is far larger — about 10.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lululemon Athletica Inc for 106 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LULU | MRVI | |
|---|---|---|
Market Cap | $10.44B | $972.90M |
Volume | 2,759,135 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $9.00 |
52-Week Low | $91.88 | $2.83 |
Typical Hold Time | 106 Days | 0 Days |
Enterprise Value | $11.20B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon stock trades at $94.09, down 54% year-to-date and near its 52-week low. The technical picture is bearish with resistance at $96 and support at $93. Fundamentally, the company reported strong revenue of $10.59B in 2025 and a net income margin of 12.78%, but faces growth concerns. Recent news highlights a securities fraud investigation and competitive pressures in athletic apparel.
The outlook is cautious due to legal overhangs and weakening sentiment, though valuation ratios like a P/E of 7.76 appear attractive. Risks include governance turmoil and consumer shifts. Analyst consensus is a $97.67 price target with a mixed buy/hold rating split, suggesting potential recovery if execution improves.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
